enGene Therapeutics Inc. (ENGN) Fair Value 2026

ENGN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.7 /10

32 fundamental signals · 2 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-28, enGene Therapeutics Inc. (ENGN) trades at $1.82, versus a $2.26 median fair value across its 2 active models — 23.9% above the current price. QOC: 4.7/10. Value Trap Risk: 21/100 (SAFE). 2/13 models active.

Key Facts

Ticker
ENGN
Price
$1.82
Quality Score
4.7/10
Value Trap Risk
21/100
Models Active
2/13
Last Updated
Strength: PWERM suggests +134.5% upside with 32% confidence
Risk: Below-average Quality Score of 4.7/10 signals weak fundamentals

Is enGene Therapeutics Inc. (ENGN) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, enGene Therapeutics Inc. (ENGN) appears undervalued as of : the median of 2 independent fair value estimates is $2.26, 23.9% above the current price of $1.82. Estimates range from $0.24 to $4.28. ENGN scores 4.7/10 on fundamental quality and 21/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ENGN’s +23.9% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy enGene Therapeutics Inc. Stock in 2026? →

What Fair Value Does Each Model Give ENGN?

2 Intrinsic Value Models vs. Current Price ($1.82)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.24 -86.7%
Option-Based · Medium Conviction
 $4.28 +134.5%

All Models Active

All 2 models are displayed above.

What Is enGene Therapeutics Inc. (ENGN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, enGene Therapeutics Inc. presents a highly debated valuation profile at its current price of $1.83. The median intrinsic value is estimated at $2.26 (+23.9% median upside), masking a wide model spread between the 1 bullish models and 1 bearish models. Model dispersion is worth noting: PWERM targets $4.28 (+134.5%), versus ML-RIV at $0.24 (-86.7%). This +221.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About ENGN?

2 of 13 models are currently active for ENGN. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for ENGN is $2.26 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ENGN Rank in Biotechnology?

Among 625 Biotechnology stocks, ENGN ranks #393 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

enGene Therapeutics Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including first-mover advantage in novel targets — shape both the opportunity set and risk profile.

Is ENGN a Value Trap?

CirclFi's Value Trap algorithm assigns ENGN a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for enGene Therapeutics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, enGene Therapeutics Inc. earns a quality score of 4.7/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +221.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ENGN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ENGN's 2 active models, average confidence is 44%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy enGene Therapeutics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

TYRATyra Biosciences, Inc.QOC 4.7LRMRLarimar Therapeutics, Inc.QOC 4.7NXTCNextCure, Inc.QOC 4.7MOLNMolecular Partners AGQOC 4.7CMMBChemomab Therapeutics Ltd.QOC 4.7MISTMilestone Pharmaceuticals Inc.QOC 4.7BSEMBioStem Technologies, Inc.QOC 3.8AXSMAxsome Therapeutics, Inc.QOC 6.6NBPNovaBridge BiosciencesQOC 5.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: TYRA · LRMR · NXTC · MOLN · CMMB · MIST · BSEM · AXSM · NBP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ENGN?

6 companies across all industries closest to ENGN’s Quality of Company score of 4.7/10.

ARBBARB IOT Group LimitedQOC 4.7BTAIBioXcel Therapeutics, Inc.QOC 4.7BZFDBuzzFeed, Inc.QOC 4.7ADSEADS-TEC Energy PLCQOC 4.7HCWCHealthy Choice Wellness Corp.QOC 4.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ARBB · BTAI · BZFD · ADSE · HCWC · NVDA

Where Does ENGN Sit in CirclFi's Biotechnology Rankings?

ENGN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About enGene Therapeutics Inc.’s Valuation?

What is enGene Therapeutics Inc.'s intrinsic value in 2026?

CirclFi puts enGene Therapeutics Inc. (ENGN)'s intrinsic value at $2.26 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.24 to $4.28. The Quality of Company score is 4.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ENGN overvalued or undervalued right now?

At $1.82, 1 of 2 active models suggest ENGN may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $2.26, 23.9% above the current price of $1.82 — a consensus view that ENGN is undervalued. The assessment depends on which methodology best fits enGene Therapeutics Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.7 mean for ENGN?

enGene Therapeutics Inc.'s QOC of 4.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ENGN?

CirclFi analyzes ENGN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is ENGN a value trap in 2026?

enGene Therapeutics Inc.'s Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, enGene Therapeutics Inc. (ENGN) has a median fair value of $2.26 — 23.9% above the current price of $1.82 — as of 2026-08-28.” Source: circlfi.com/stock/ENGN/ · Methodology
Primary sources for this ENGN valuation
  • Financial statements: enGene Therapeutics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001980845) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ENGN as of ; valuations recomputed .